The Sulfasalazine Market Size is valued at USD 2.02 Bn in 2022 and is predicted to reach USD 3.13 Bn by the year 2031 at a 5.2 % CAGR during the forecast period for 2023-2031.
Sulfasalazine, an anti-inflammatory drug, used to treat inflammatory gut diseases like Crohn's disease and ulcerative colitis. In the body, sulfasalazine aids in reducing inflammation. Sulfasalazine contains two active components: sulfapyridine and 5-aminosalicylic acid (5-ASA). These components work together to provide therapeutic effects.
The market's expansion is attributable to the rising incidence of ankylosing spondylitis and inflammatory bowel disorders (IBD), as well as to increased public awareness of these conditions and the introduction of cutting-edge treatments. The market has expanded as a result of the rising incidence of ankylosing spondylitis and inflammatory bowel illnesses, increased public awareness of these conditions, and the introduction of cutting-edge treatments.
However, the pandemic caused global supply chains to become disrupted, which had an impact on the manufacturing, delivery, and accessibility of medicines. This might have affected the availability of sulfasalazine and other drugs, causing shortages or delays in getting the treatment.
Competitive Landscape
Some Major Key Players In The Sulfasalazine Market:
- Pfizer Inc.
- Teva Pharmaceuticals
- Mylan N.V
- Dr Reddy's Laboratories
- Zydus Cadila
- Sun Pharmaceutical Industries
- Aspen Pharmacare
- Apotex Inc.
- Sandoz (a division of Novartis)
- Lupin Limited
Market Segmentation:
The Sulfasalazine Market is segmented on the basis of product, application, distribution channel, patient demographics, disease severity, prescription type, end-user, and patient education and support. As Per the product segment, the market is segmented as Generic Sulfasalazine and Branded Sulfasalazine. The application segment includes Rheumatoid Arthritis, Inflammatory Bowel Diseases, Crohn's Disease, and Ulcerative Colitis. Distribution channel includes Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Specialty Clinics. The patient demographics segment includes adults and paediatrics.
By disease severity, the market is segmented into Mild, Moderate, and Severe. Based on prescription, the market is segmented as Over-the-Counter (OTC) with medical supervision and Prescription-only. By prescription type, the market is segmented into hospitals and clinics. End-user segment comprises Hospitals, Clinics, Ambulatory Surgical Centers, and Homecare. By patient education and support, the market is segmented into Patient Support Programs, Educational Material, and Healthcare Professional Training.
Based On Application, The Ulcerative Colitis Segment Is Accounted As A Major Contributor In The Sulfasalazine Market.
The Ulcerative Colitis category is expected to hold a major share of the global Sulfasalazine Market in 2022. One of the main cause propelling the expansion of this application segment is the increasing prevalence of ulcerative colitis and the growing awareness of the condition. Inflammatory bowel disease (IBD), known as ulcerative colitis, damages the rectum and large intestine's inner lining. Sulfasalazine is used in Ulcerative Colitis due to regulatory approvals that have been established and its inclusion in treatment recommendations. Abdominal pain, diarrhoea, exhaustion, weight loss, and blood in the stool are all signs of ulcerative colitis.
The Hospitals Segment Witnessed Expansion At A Rapid Rate.
The hospital segment is expected to grow at a rapid rate in the global Sulfasalazine Market. Hospitals provide critical healthcare facilities with specialized care to patients suffering from various medical conditions. When oral delivery fails to be feasible, hospitals have the infrastructure to provide sulfasalazine intravenously. Sulfasalazine's role in disease management is highlighted by regular monitoring of patients taking it and the significance of adhering to the recommended dosage schedule.
In The Region, The North American Sulfasalazine Market Holds A Significant Revenue Share.
The North American sulfasalazine Market is expected to record the maximum market share in revenue in the near future. The growing demand for sulfasalazine in North America is a result of autoimmune disorders, including inflammatory bowel disease and rheumatoid arthritis, becoming more common. The region's strong sulfasalazine awareness and established healthcare infrastructure also contribute to the market's expansion. Due to rising disposable incomes, rising healthcare costs, and increased sulfasalazine awareness in the Asia Pacific is anticipated to grow significantly.
Sulfasalazine Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 2.02 Bn |
|
Revenue Forecast In 2031 |
USD 3.13 Bn |
|
Growth Rate CAGR |
CAGR of 5.2 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product Type, By Application, By Distribution Channel, By Patient Demographics, By Disease Severity, By Prescription Type, By End-user, By Patient Education and Support |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Pfizer Inc., Teva Pharmaceuticals, Mylan N.V., Dr. Reddy's Laboratories, Zydus Cadila, Sun Pharmaceutical Industries, Aspen Pharmacare, Apotex Inc., Sandoz (a division of Novartis), Lupin Limited. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
